C069P: Brolucizumab Biosimilar, VEGF-A Monoclonal Antibody
Recombinant Humanized IgG1 Monoclonal Antibody.
Specificity/Sensitivity: The in vivo grade brolucizumab biosimilar specifically binds to the human vascular endothelial growth factor A (VEGF-A).
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by brolucizumab.BP000991-PKA-241: Recombinant Human VEGFR1 D17
Source: Insect Cells-derived.
The activity of FLT1/Fc was determined by its ability to inhibit the VEGF-dependent proliferation of human umbilical vein endothelial cells. The ED50 for this effect is typically 10-30 ng/ml, corresponding to a specific activity of 33,333.33-100,000 units/mg.
Purity > 95%, by SDS-PAGE.PA006153-PA1771: Neuropilin-2 Polyclonal Antibody
Rabbit Polyclonal Antibody;
Applications: WB;
Reactivity: Human, Rat, Mouse;
Isotype: Rabbit IgG.PA004071-PA1752: NRP1 Polyclonal Antibody
Rabbit Polyclonal Antibody;
Applications: WB;
Reactivity: Human, Rat, Mouse;
Isotype: Rabbit IgG.BP000027-GD1: Recombinant Human VEGF165 (aa 27-191) Protein
Source: HEK 293 cell-derived.
The VEGF activity is measured in a cell proliferation assay using human umbilical vein endothelial cells (HUVEC). The ED50 for this effect is typically 1-5 ng/ml.
Endotoxin: < 1.0 EU per ug of the protein by the LAL method.
Purity: > 95% by SDS-PAGE under reducing conditions.BP000027-C083: Recombinant Human Vascular Endothelial Growth Factor Isoform 165 (VEGF165) Protein
Source: E. coli-derived.
Purity: > 95% by SEC-HPLC and reducing SDS-PAGE.
Endotoxin: < 0.1 ng/ug (1 IEU/ug).BP000027-CYT-200: Recombinant Human VEGF (121 a.a.) Protein, Sf9
Source: Sf9, Insect Cells-derived.
Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 2-5 ug/ml corresponding to a Specific Activity of 200,000-500,000 IU/mg.
Purity: >90% by SDS-PAGE and RP-HPLC.BP000027-CYT-225: Recombinant Human Vascular Endothelial Growth Factor (VEGF) Protein, HEK
Source: HEK 293 (Human Embryonic Kidney cell line)-derived.
Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 1-6 ug/ml corresponding to a Specific Activity of 166,667-1,000,000 IU/mg.
Purity: > 95% by SDS-PAGE.BP000027-CYT-226: Recombinant Mouse Vascular Endothelial Growth Factor (VEGF) Protein, Sf9
Source: Baculovirus Sf9 cells-derived.
The ED50 range, determined by the dose-dependent proliferation of human umbilical vein endothelial cells (HUVEC) (measured by 3H-thymidine uptake) is 1-2 ug/ml, corresponding to a specific activity of 1x106 Units/mg.
Purity: > 95% by SDS-PAGE and RP-HPLC.BP000027-CYT-241: Recombinant Human Vascular Endothelial Growth Factor (VEGF) Protein
Source: E. coli-derived.
Determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 1-8 ug/ml corresponding to a Specific Activity of 125,000-1,000,000 IU/mg.
Purity: > 98% by SDS-PAGE and RP-HPLC.